Publikationen

The current R&D system is driven by market forces, not health needs, and relies overwhelmingly on the patent system to recoup R&D costs by charging high prices for the medical tools that reach the market. The two key problems that this system creates is addressed in this briefing paper.

This report outlines some of the strategies, tools and policies that have supported the scaling up of treatment during the past decade as well as those that can address persistent or new challenges. The results are presented from a 23-country survey of how consistently these strategies are being implemented.

This document shows how health programmes can be designed to deliver antiretroviral drugs at a communits level.

The 15th edition of this publication gives an overview on drug prices and their quality, introduces the main actors in the field and the threats and challenges in keeping the prices of ARVs down.

This document serves as an update to “Out of the Dark”, a report published by MSF in October 2011, highlighting the need to prioritise the long-neglected area of paediatric tuberculosis (TB). This update will outline the key improvements and setbacks—the ‘highlights’ and ‘lowlights’—that have occurred over the last year.

This document serves as an update to “Out of the Dark”, a report published by MSF in October 2011, highlighting the need to prioritise the long-neglected area of paediatric tuberculosis (TB). This update will outline the key improvements and setbacks—the ‘highlights’ and ‘lowlights’—that have occurred over the last year.

Normal 0 21 false false false DE X-NONE X-NONE

Aktuelle Entwicklungen im weltweiten Patentrecht verschärfen das Problem des Zugangs zu bezahlbaren Medikamenten

/* Style Definitions */ table.MsoNormalTable {mso-style-name:"Normale Tabelle"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-qformat:yes; mso-style-parent:""; mso-padding-alt:0cm 5.4pt 0cm 5.4pt; mso-para-margin-top:0cm; mso-para-margin-right:0cm; mso-para-margin-bottom:10.0pt; mso-para-margin-left:0cm; line-height:115%; mso-pagination:widow-orphan; font-size:11.0pt; font-family:"Calibri","sans-serif"; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:"Times New Roman"; mso-fareast-theme-font:minor-fareast; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin;}

This report aims to inform and help ARV treatment programmes procure low-cost, quality ARVs effectively and efficiently.

The HIV/AIDS crisis and the significant disparities in access to AIDS treatment between rich and poor countries provide a striking example of what is at stake in FTAA negotiations for people in the Americas.